TORSEMIDE by Teva is henle, where it inhibits the na/k/2cl-carrier system. Approved for edema associated with heart failure, renal disease, hepatic disease and 2 more indications. First approved in 2002.
Drug data last refreshed 4h ago
Henle, where it inhibits the Na/K/2Cl-carrier system. Clinical pharmacology studies have confirmed this site of action in humans, and effects in other segments of the nephron have not been demonstrated. Diuretic activity thus correlates better with the rate of drug excretion in the urine than with…
Worked on TORSEMIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.